[ad_1]
PApparently, fizer has cut its delivery targets for its coronavirus vaccine due to supply chain issues. Now half the original amount is expected, the Wall Street Journal reported Thursday.
Instead of the 100 million deliveries actually expected, the report says Pfizer now only plans about 50 million by the end of the year.
The background is insufficient quality of raw materials. The expansion of the supply chain is taking longer than expected, the “Wall Street Journal” quoted a spokeswoman for the company. Initially, a more detailed statement from the American pharmaceutical company was not available. Pfizer is developing the vaccine together with Germany’s Biontech.
The news weighed on US trading for Pfizer shares, which were just 2.4 percent in the red shortly before the close of trading on Wall Street. The US Dow Jones Standard Value Index gave up its initial gains.
The British Medicines Agency granted Pfizer and Biontech emergency approval for their corona vaccine on Wednesday. The UK is the first country to issue a certificate of authorization for the vaccine. The US Food and Drug Administration and the European Medicines Agency Ema are also reviewing these applications.
